YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With…
Novavax stock (NVAX) fell on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a "low" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last w…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
Wall Street closed in the green on Friday after the September nonfarm payrolls report came in cooler than economists expected. The blue-chip Dow ended up 0.5%, the benchmark S&P 500 gained 0.7%, and the tech-focused Nasdaq Composite advanc…
Both Moderna MRNA and BioNTech BNTX are leading biotechs at the forefront of messenger RNA (mRNA) technology. The companies rose to prominence with their respective COVID-19 vaccines, but their investment stories now extend well beyond the…
Company Logo AI, cloud and HPC are accelerating virtual screening and precision medicine, expanding adoption across pharma, biotech and CROs in oncology, neurology, rare and infectious diseases. Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "…
[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://see…
In mid-September 2026, Pfizer Canada and BioNTech announced Health Canada's approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals aged 6 months and older, aligning with 2026–2027 public health recommendations. A few days ea…
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targ…
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company. Continue Reading
Quick Read MRNA has surged 506% in 2026 on a top-line win from the 1,137-patient INTerpath-001 melanoma trial, with full Phase 3 data due October 24. BNTX's 5% gain versus Moderna's 506% confirms the market is betting on intismeran specifi…
BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case. On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" r…
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology. Continue Reading
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a…
Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer…
BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it…
BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy.…
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung c…
On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times c…
BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of car…
[Wall Street New York City] aluxum/E+ via Getty Images Wall Street’s major averages closed higher on Friday after the latest consumer inflation report came in largely in line with expectations. The blue-chip Dow (DJI [https://seekingalpha.…
[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILITY WAT…
Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both secto…
Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company's ability to stabilize earnings and offset the continued decline in COVID-19 product sales. A key catalyst has been a solid second-…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Moderna MRNA shares have surged 143% in the past month, driven largely by recently announced positive late-stage results for a personalized mRNA-based cancer therapy being developed in partnership with Merck MRK. Oncology Win Highlights Mo…
Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies. BMO analyst Evan Seigerman cut Amgen's…
Medical research testing ©Pixnio BioNTech SE (NASDAQ:BNTX) shares fell 1.2% to $102.55 in premarket trading after BMO Capital downgraded the stock and reduced its price target. BMO lowered its rating on BioNTech from Outperform to Market P…
BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely to demonstrate effectiveness. The…
[Covid-19 vaccine in a vial, immunization and treatment of infection] Kittisak Kaewchalun An Army doctor is working with Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth to investigate whether U.S. troops died from…
BioNTech (NASDAQ: BNTX) and Moderna (NASDAQ: MRNA) burst onto the scene during the pandemic. Both developed and marketed some of the most successful mRNA-based coronavirus vaccines and were handsomely rewarded for it. However, their financ…
BioNTech (NASDAQ: BNTX) has lagged the market this year. The company's shares have climbed just 6% as of writing, compared with the S&P 500's 12% gain. The biotech's performance looks even worse once we zoom out. Over the past five years,…
Quick Read MRNA climbed 6% as traders read GSK's Phase III mRNA flu commitment as platform validation rather than a competitive threat to mFlusvia. Moderna's Phase III melanoma win with MRK as co-developer rekindled platform interest, and…
Quick Read NVAX jumped 7% on unverified Matrix-M oncology speculation, even as the real story had already quietly resumed: high-teens royalties on Sanofi's Nuvaxovid global net sales restarted for 2026 and 2027. IBB gained just 0.2% while…
BioNTech BNTX announced that it has discontinued the phase II BNT122-01 study evaluating autogene cevumeran for the treatment of patients with high-risk stage II or stage III colorectal cancer ("CRC") whose tumors had been surgically remov…